This proposed CTDD program will help translate the enormous resource of high- throughput cancer genome characterizations into functionally validated, cancer-genotype based therapeutic targets. Over the past several years, members of this project have developed powerful tools and strategies for functionally annotating cancer genomes. These have enabled the identification and validation over fifty cancer genes, several of which are compelling therapeutic targets. Here, we propose to synthesize and optimize those strategies into a unified blueprint that can be applied across many tumor types. At the core of our philosophy is the use of powerful computational tools to narrow the extent of the genome that must be surveyed functionally. This enables the use of more precise human and mouse models to assess drivers and dependencies and approaches to combinatorial interactions that could not be carried out on a genome wide scale. We will apply these tools to select cancer types and gene sets in order to identify new oncogenic drivers, genotype-specific cancer dependencies, and to test strategies for the systematic identification of targets for combination therapies. We envision the impact of our project not only as the identification of genomically informed targets for several tumor types but also as providing tools and strategies that can be used throughout the consortium and the community.

Public Health Relevance

Technological breakthroughs in genomics have enabled a comprehensive characterization of the genetic abnormalities in many human tumor types. What is needed now are equally powerful methods for translating these genomic characterizations into functionally validated cancer therapeutic targets and ultimately new treatments. We propose to synthesize and optimize informatics, functional, and in vivo strategies into a unified blueprint that can be applied across many tumor types.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-V (J1))
Program Officer
Gerhard, Daniela
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cold Spring Harbor Laboratory
Cold Spring Harbor
United States
Zip Code
Cho, Hyejin; Herzka, Tali; Zheng, Wu et al. (2014) RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov 4:318-33
Catanzaro, Joseph M; Sheshadri, Namratha; Pan, Ji-An et al. (2014) Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. Nat Commun 5:3729
Sun, Guoli; Krasnitz, Alexander (2014) Significant distinct branches of hierarchical trees: a framework for statistical analysis and applications to biological data. BMC Genomics 15:1000
Aksoy, Bülent Arman; Demir, Emek; Babur, Özgün et al. (2014) Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles. Bioinformatics 30:2051-9
Dow, Lukas E; Nasr, Zeina; Saborowski, Michael et al. (2014) Conditional reverse tet-transactivator mouse strains for the efficient induction of TRE-regulated transgenes in mice. PLoS One 9:e95236
Öhlund, Daniel; Elyada, Ela; Tuveson, David (2014) Fibroblast heterogeneity in the cancer wound. J Exp Med 211:1503-23
Huang, Chun-Hao; Lujambio, Amaia; Zuber, Johannes et al. (2014) CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev 28:1800-14
Chio, Iok In Christine; Yordanov, Georgi; Tuveson, David (2014) MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors. J Natl Cancer Inst 106:
Aksoy, Bulent Arman; Gao, Jianjiong; Dresdner, Gideon et al. (2013) PiHelper: an open source framework for drug-target and antibody-target data. Bioinformatics 29:2071-2
Krasnitz, Alexander; Sun, Guoli; Andrews, Peter et al. (2013) Target inference from collections of genomic intervals. Proc Natl Acad Sci U S A 110:E2271-8